Isoniazid resistance levels of Mycobacterium tuberculosis can largely be predicted by high-confidence resistance-conferring mutations.

Pauline Lempens, Conor J Meehan, Koen Vandelannoote, Kristina Fissette, Pim de Rijk, Armand Van Deun, Leen Rigouts, Bouke C de Jong
Author Information
  1. Pauline Lempens: Unit of Mycobacteriology, Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium. plempens@itg.be.
  2. Conor J Meehan: Unit of Mycobacteriology, Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
  3. Koen Vandelannoote: Unit of Mycobacteriology, Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
  4. Kristina Fissette: Unit of Mycobacteriology, Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
  5. Pim de Rijk: Unit of Mycobacteriology, Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
  6. Armand Van Deun: Unit of Mycobacteriology, Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
  7. Leen Rigouts: Unit of Mycobacteriology, Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
  8. Bouke C de Jong: Unit of Mycobacteriology, Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.

Abstract

The majority of Mycobacterium tuberculosis isolates resistant to isoniazid harbour a mutation in katG. Since these mutations cause a wide range of minimum inhibitory concentrations (MICs), largely below the serum level reached with higher dosing (15 mg/L upon 15-20 mg/kg), the drug might still remain partly active in presence of a katG mutation. We therefore investigated which genetic mutations predict the level of phenotypic isoniazid resistance in clinical M. tuberculosis isolates. To this end, the association between known and unknown isoniazid resistance-conferring mutations in whole genome sequences, and the isoniazid MICs of 176 isolates was examined. We found mostly moderate-level resistance characterized by a mode of 6.4 mg/L for the very common katG Ser315Thr mutation, and always very high MICs (≥19.2 mg/L) for the combination of katG Ser315Thr and inhA c-15t. Contrary to common belief, isolates harbouring inhA c-15t alone, partly also showed moderate-level resistance, particularly when combined with inhA Ser94Ala. No overt association between low-confidence or unknown mutations, except in katG, and isoniazid resistance (level) was found. Except for the rare katG deletion, line probe assay is thus not sufficiently accurate to predict the level of isoniazid resistance for a single mutation in katG or inhA.

References

  1. Drugs. 2014 Jun;74(8):839-54 [PMID: 24846578]
  2. Diagn Microbiol Infect Dis. 2015 May;82(1):49-53 [PMID: 25749461]
  3. PLoS One. 2015 Mar 23;10(3):e0119628 [PMID: 25799046]
  4. Int J Tuberc Lung Dis. 2012 Jan;16(1):24-31 [PMID: 22236841]
  5. Syst Biol. 2001 Nov-Dec;50(6):913-25 [PMID: 12116640]
  6. Int J Tuberc Lung Dis. 1999 Aug;3(8):703-10 [PMID: 10460103]
  7. Int J Tuberc Lung Dis. 1999 Oct;3(10 Suppl 2):S231-79 [PMID: 10529902]
  8. Antimicrob Agents Chemother. 2013 Aug;57(8):3620-7 [PMID: 23689727]
  9. Bull World Health Organ. 1963;29:565-78 [PMID: 14102034]
  10. Clin Pharmacokinet. 1979 Nov-Dec;4(6):401-22 [PMID: 391461]
  11. Microbiology. 2002 Oct;148(Pt 10):2967-73 [PMID: 12368430]
  12. Int J Tuberc Lung Dis. 2008 Feb;12(2):139-45 [PMID: 18230245]
  13. Am J Respir Crit Care Med. 2010 Sep 1;182(5):684-92 [PMID: 20442432]
  14. Int J Tuberc Lung Dis. 2017 Jan 1;21(1):123-124 [PMID: 28157478]
  15. J Clin Microbiol. 2015 Jun;53(6):1908-14 [PMID: 25854485]
  16. Bioinformatics. 2014 May 1;30(9):1312-3 [PMID: 24451623]
  17. Tuberculosis (Edinb). 2011 Jan;91(1):1-7 [PMID: 20980199]
  18. Int J Tuberc Lung Dis. 2014 Oct;18(10):1180-7 [PMID: 25216831]
  19. Int J Tuberc Lung Dis. 2014 Oct;18(10):1188-94 [PMID: 25216832]
  20. Antimicrob Agents Chemother. 2003 Apr;47(4):1241-50 [PMID: 12654653]
  21. Antimicrob Agents Chemother. 1995 Nov;39(11):2472-7 [PMID: 8585728]
  22. Syst Biol. 2015 Nov;64(6):1032-47 [PMID: 26227865]
  23. BMC Med. 2016 Mar 23;14:31 [PMID: 27005572]
  24. Bioinformatics. 2010 Aug 1;26(15):1834-40 [PMID: 20529891]
  25. Antimicrob Agents Chemother. 2015 Oct 12;60(1):92-8 [PMID: 26459901]
  26. Pneumonol Alergol Pol. 2013;81(4):298-307 [PMID: 23744165]
  27. J Clin Microbiol. 2001 Apr;39(4):1591-4 [PMID: 11283093]
  28. Int J Tuberc Lung Dis. 2016 Aug;20(8):1099-104 [PMID: 27393546]
  29. Microbiol Spectr. 2014 Aug;2(4):MGM2-0014-2013 [PMID: 26104204]
  30. Antimicrob Agents Chemother. 2008 Sep;52(9):3369-76 [PMID: 18591265]
  31. PLoS Med. 2009 Feb 10;6(2):e2 [PMID: 19209951]
  32. Bioinformatics. 2007 Jan 1;23(1):127-8 [PMID: 17050570]

Grants

  1. 311725/European Research Council

MeSH Term

Antitubercular Agents
Bacterial Proteins
Catalase
Drug Resistance, Bacterial
Humans
Isoniazid
Microbial Sensitivity Tests
Mutation
Mycobacterium tuberculosis
Oxidoreductases
Tuberculosis

Chemicals

Antitubercular Agents
Bacterial Proteins
Oxidoreductases
Catalase
katG protein, Mycobacterium tuberculosis
InhA protein, Mycobacterium
Isoniazid

Word Cloud

Created with Highcharts 10.0.0katGisoniazidresistancemutationsisolatesmutationlevelinhAtuberculosisMICsMycobacteriumlargelypartlypredictassociationunknownresistance-conferringfoundmoderate-levelcommonSer315Thrc-15tmajorityresistantharbourSincecausewiderangeminimuminhibitoryconcentrationsserumreachedhigherdosing15 mg/Lupon15-20 mg/kgdrugmightstillremainactivepresencethereforeinvestigatedgeneticphenotypicclinicalMendknownwholegenomesequences176examinedmostlycharacterizedmode64 mg/Lalwayshigh≥192 mg/LcombinationContrarybeliefharbouringalonealsoshowedparticularlycombinedSer94Alaovertlow-confidenceexceptExceptraredeletionlineprobeassaythussufficientlyaccuratesingleIsoniazidlevelscanpredictedhigh-confidence

Similar Articles

Cited By